anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute kidney injury (AKI) in sepsis is a vital and dangerous organ failure caused by an infection-induced dysregulation of the host reaction. Malvidin possesses significant anti-inflammatory and antioxidant bioactivities. This study explored the critical roles of malvidin in sepsis AKI and the crosstalk among mitochondrial function, nucleotide-binding oligomerization-like receptor 3 (NLRP3) inflammasome and nuclear factor erythroid 2 (Nrf2) signaling pathway. First, C57BL/6 mice were administered lipopolysaccharide intraperitoneally for 6 h to create an AKI model of sepsis. Hematoxylin-eosin staining and serum biomarker assays showed that malvidin protected from AKI in sepsis. Real-time fluorescence quantitative polymerase chain reaction analysis revealed that malvidin was able to inhibit inflammatory cytokines and mediators. Western blot assays indicated that malvidin suppressed NLRP3 inflammasome activation and enhanced antioxidant properties. Additionally, human renal tubular epithelial cells were stimulated by lipopolysaccharide/adenosine triphosphate to establish an NLRP3 inflammasome activation model in vitro, and in line with findings in vivo, malvidin significantly inhibited NLRP3 inflammasome activation. Furthermore, our data indicate that malvidin restored mitochondrial quality and function, reduced reactive oxygen species production, increased mitochondrial membrane potential, enhanced mitochondrial DNA copy number, and promoted peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) nuclear translocation. Moreover, inhibitor blockade assays indicated that both PGC-1α and Nrf2 affected the inhibition of the NLRP3 inflammasome by malvidin. Finally, immunoprecipitation assays showed that malvidin promoted PGC-1α and Nrf2 interactions. Overall, malvidin alleviated lipopolysaccharide-induced sepsis AKI, improved mitochondrial function and mitochondrial biogenesis, and inhibited the NLRP3 inflammasome through the PGC-1α/Nrf2 signaling pathway, suggesting that malvidin might translate into clinical applications for sepsis AKI therapy.
A novel multi-arm polyethylene glycol (PEG) (I) and preparation method thereof. Active derivatives (II) based on the multi-arm PEG. Gels formed of the active derivatives. Drug conjugates formed of the active derivatives and drug molecules and uses thereof in medical preparation. The multi-arm PEG is formed by polymerizing ethylene oxide with pentaerythritol oligomers as initiator, wherein PEG is the same or different and is a -(CH 2 CH 2 O) m -, the average value of m is an integer of 3-1000,  l  is an integer more than or equal to 2. An 8-arm PEG is preferred, wherein  l  is equal to 3. The active derivatives (II) comprise link groups X attached to PEG and active end groups F attached to X.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to compositions and methods of bleaching of teeth. There are offered dental coating liquids containing bleaching particles, such as hydroxyapatite particles, and organosiloxane polymer. Said organosiloxane polymer is presented with hydrophilic organosiloxane polymer, e.g. dimeticone/acrylate copolymer or dimeticone (polydimethylsiloxane) copolyol. ^ EFFECT: dental application of the liquid creates a dental coating and ensures dental bleaching. ^ 18 cl, 2 tbl, 9 ex
Pulpotomy is the most widely accepted technique for treating primary teeth with deep carious lesion, pulp exposure during the operatory process or after a traumatic pulp exposure. Mineral trioxide aggregate (MTA) is one such material that has shown tremendous potential for regeneration. Biodentine™ (hydraulic silicate cement) is a novel dental material with high mechanical characteristics as well as superior biocompatibility and bioactive behaviour. Nowadays, chicken eggshell powder (CESP) (a natural calcium-rich source) is achieving wide acceptance in the medical and dental fields. Tea tree oil is the essential oil extracted from the Australian native Melaleuca alternifolia or the tea tree. To date, there is insufficient evidence to properly evaluate Tea Tree Oil- Eggshell Powder as a pulpotomy agent in primary teeth; thus, the current study aimed to assess and compare clinical and radiographical success of Tea Tree Oil- Eggshell Powder and Biodentine as pulpotomy agents in primary teeth.
PROBLEM TO BE SOLVED: To remove malodors and to prevent a bedsore or to suppress the progression of this bedsore by coating a sheet-like deodorant material obtd. by incorporating ferrous sulfate into a cellulosic sheet-like member and oxidizing this ferrous sulfate to basic ferric sulfate by an air permeable film and heat sealing the peripheral edges of this film. SOLUTION: 1000 liter aq. ferrous sulfate soln. is prepd. by diluting 150kg ferrous sulfate FeSO4 .7H2 O to make 1000 liters in total volume. Paper towel raw paper (weighing 47kg/m<2> , width 850mm) is coated with the prepd. aq. ferrous sulfate soln. at 80ml per 1m<2> raw paper by using a roll coater, is then heated to a moisture content of 10% and is taken up after drying. This paper is cut by a cutter, by which the sheet-like deodorant material D of 810mm in width and 910mm in length is prepd. The prepd. sheet-like deodorant material D is coated by the air permeable film (width 850mm, length 950mm) and the four sides thereof are subjected to sealing (h) by heating, by which the waterproof, deodorant and bedsore preventive sheet A is prepd.
PURPOSE: A composition containing a honeybush extract or fermented liquid thereof is provided to reduce the length and depth of wrinkles and improve anti-wrinkling effect. CONSTITUTION: A cosmetic composition for improving anti-wrinkling contains a honeybush extract or fermented liquid thereof as an active ingredient. The extract is prepared using water, low carbon number alcohol, or a mixture thereof. The fermented liquid is prepared by inoculating lactic acid bacteria into animal milk; a step of mixing with a carbon source and the honeybush extract; and a step of fermenting the mixture at 35-38 deg.C. for 1-3 days. The lactic acid bacteria are Streptococcus thermophilus. The extract or fermented liquid additionally contains other anti-wrinkling ingredients such as retinol, retinyl palmitate, adenosine, polyethoxylated retinamide, collagen, TGF, or animal placenta-derived proteins.
Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
BACKGROUND: Providing primary care for people with frailty can be challenging due to an increased risk of adverse outcomes and use of potentially inappropriate medications which may exacerbate characteristics of frailty. eConsult is a service where primary care providers can receive timely specialist advice for their patients through a secure web-based application. We aimed to develop a classification system to characterize medication-focused eConsult questions for older adults with frailty and assess its usability.
METHODS: A classification system was developed and refined over three cycles of improvement through a cross-sectional study of 35 cases categorized as medication-focused from cases submitted in 2019 for patients aged 65 or older with frailty through the Champlain BASE eConsult service (Ontario, Canada). The final classification system was then applied to each case.
RESULTS: The classification system contains 5 sections: (1) case descriptives; (2) intent and type of question; (3) medication recommendations and additional information in the response; (4) medication classification; and (5) potentially inappropriate medications. Among the 35 medication-focused cases, the most common specialties consulted were endocrinology (9 cases, 26%) and cardiology (5 cases, 14%). Medication histories were available for 29 cases (83%). Many patients were prescribed potentially inappropriate medications based on explicit tools (AGS Beers Criteria®, STOPPFall, Anticholinergic Cognitive Burden Scale, ThinkCascades) yet few consults inquired about these medications.
CONCLUSION: A classification system to describe medication-related eConsult cases for patients experiencing frailty was developed and applied to 35 eConsult cases. It can be applied to more cases to identify professional development opportunities and enhancements for eConsult services.
The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
Cystic fibrosis-related diabetes (CFRD) is one of the most common co-morbidities seen in CF and significantly increases morbidity and mortality. The prevalence of CFRD increases with age with approximately 20% of adolescents and 50% of adults in the 3rd and 4th decade of life carrying the diagnosis. Although a diagnosis of CFRD is uncommon in children less than 10 years of age, research studies show that abnormal glucose tolerance is found in about 40% of CF toddlers and school-age children. Mechanisms leading to the development of CFRD are incompletely understood. For several years, the predominant theory of pancreatic endocrine dysfunction was based on the theory of "collateral damage" which results in impairment of β-cell function due to loss of islet cells. In addition to experiencing reduced beta cell mass, individuals with CF have a diminished incretin effect that contributes to impaired insulin secretion. Postprandial hyperglycemia is not uncommon for individuals with CF irrespective of their glucose tolerance and during an OGTT failure to suppress glucagon results in hyperglycemia. Unfortunately, mechanisms involved in dysregulated glucagon release and its contribution to hyperglycemia in CF are poorly understood.

The CF diet is typically high in energy-dense, nutrient-poor foods. Individuals with CF require high-energy, high-fat diets to maintain their hypermetabolic state and offset malabsorption, with current CF dietary guidelines recommending an energy intake of 1.2 to 1.5 times that of the general population. To date, there is a paucity of studies that rigorously investigate the metabolic sequelae that high GI foods and SSB have on the metabolic profile of individuals with CF. The study team proposes that a diet high is SSBs and high GI foods induces more oxidative stress due to postprandial hyperglycemia, impairs insulin secretion, and exacerbates glucose abnormalities in CF.
In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
An identification and characterization of a calcineurin interacting (CNI) protein effective to enhance immunosuppressive effects of calcineurin-targeted immunosuppressants by potentiating an interaction of an immunophilin with calcineurin is described herein. One embodiment of the invention is the CNI polypeptide encoded by the CNI gene of Saccharomyces cerevisiae. Polynucleotides encoding a CNI protein are also described. Also described are yeast cells carrying mutations in the CNI gene. Further, a method of identifying a small molecule immunosuppressant compound is described. The methods include the use of a cell-based two hybrid protein-protein interaction assay, wherein one of two fusion hybrid proteins in a cell contains a subunit of calcineurin, and the other of two fusion hybrid proteins contains an immunophilin.
PROBLEM TO BE SOLVED: To solve problems associated with the limited amount of raw materials from which antibacterial agents can be obtained, and to provide an inexpensive and constant mass-production method of natural antibacterial agents, which can be used not only in food industry but also widely in other industrial fields, using an antibacterial substance derived from rush. SOLUTION: Dried rush is ground to powder and taken as an oral medication in tablet form or in powder. Alternatively, a liquid antibacterial agent is provided using extracts of rush ingredients. Since the antibacterial agent prevents the growth of and destroys harmful microorganisms, the agent can be used in food industry as a bacteriostat or a bactericide. When used as a food additive to prevent food spoilage, the agent is safer than chemical agents. The agent is safe when taken by a sitotoxism patient.
OBJECTIVES: Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility are required. This work sought to further investigate the putative antiviral activity of probenecid against SARS-CoV-2.
METHODS: Vero E6 cells were preincubated with probenecid, or control media for 2 h before infection (SARS-CoV-2/Human/Liverpool/REMRQ0001/2020). Probenecid or control media was reapplied, plates reincubated and cytopathic activity quantified by spectrophotometry after 48 h. In vitro human airway epithelial cell (HAEC) assays were performed for probenecid against SARS-CoV-2-VoC-B.1.1.7 (hCoV-19/Belgium/rega-12211513/2020; EPI_ISL_791333, 2020-12-21) using an optimized cell model for antiviral testing. Syrian golden hamsters were intranasally inoculated (SARS-CoV-2 Delta B.1.617.2) 24 h prior to treatment with probenecid or vehicle for four twice-daily doses.
RESULTS: No observable antiviral activity for probenecid was evident in Vero E6 or HAEC assays. No reduction in total or subgenomic RNA was observed in terminal lung samples (P > 0.05) from hamsters. Body weight of uninfected hamsters remained stable whereas both probenecid- and vehicle-treated infected hamsters lost body weight (P > 0.5).
CONCLUSIONS: These data do not support probenecid as a SARS-CoV-2 antiviral drug.
In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
This is a study of early bactericidal activity (EBA) in treatment-naïve patients with active pulmonary tuberculosis. This prospective, randomized, open-label study that will compare the effect of monotherapy with each of four dose levels of AZD5847 to that of an active control (Rifafour administered orally once daily) on the concentration of Mycobacterium tuberculosis (M. tb) in expectorated sputum (colony-forming units per mL of sputum). Daily quantitative sputum cultures will be performed during treatment and analyzed by investigators who will be blinded to the assigned treatment. The duration of therapy will be 14 days in order to support an assessment of early bactericidal activity (days 0-2) and sterilizing activity (days 3-14). Because of the risk of emergence of drug resistance in TB patients treated with a single active drug, regulatory and ethical requirements restrict monotherapy to a maximum duration of 14 days (EMEA Draft TB Guidance 2008). The study will utilize a standard design and will thus support comparison with other marketed and investigational antimycobacterial agents (Donald and Diacon 2008). The primary aim of the study is to assess the EBA 0-14 of AZD5847 at four different doses and schedules (500 mg once daily, 500 mg twice daily, 1200 mg once daily, and 800 mg twice daily) in subjects with newly-diagnosed sputum smear positive pulmonary TB. The secondary aim is to assess the EBA 0-2 and EBA 2-14 of AZD5847 at the above doses.
Systems, apparatus, and methods are disclosed for conveying signals between a patient and monitoring and treatment devices. An EP system provides large-signal input protection and RF ablation signal noise suppression while preserving the integrity of relevant components of small signals. The EP system has a low-noise amplifier topology with minimal hardware filtering. An input protection circuit shunts to ground signals with amplitude above an ablation voltage. An RF filter circuit linearly attenuates the signals between 300 kHz and 600 kHz. A low-frequency feedback circuit drives a common mode node of the RF filter circuit for additional attenuation. A signal amplification circuit amplifies the signals between 0.01 Hz and 1000 Hz. A fast recovery circuit feeds back a low-frequency voltage signal to the signal amplification circuit to gradually reduce offset voltage of the signals. A high-resolution A/D converter converts the signals from the signal amplification circuit to clean digital signals.
The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
BACKGROUND: Although polyp size dictates surveillance intervals, endoscopists often estimate polyp size inaccurately. We hypothesized that an intervention providing didactic instruction and real-time feedback could significantly improve polyp size classification.
METHODS: We conducted a multicenter randomized controlled trial to evaluate the impact of different components of an online educational module on polyp sizing. Participants were randomized to control (no video, no feedback), video only, feedback only, or video + feedback. The primary outcome was accuracy of polyp size classification into clinically relevant categories (diminutive [1-5mm], small [6-9mm], large [≥10mm]). Secondary outcomes included accuracy of exact polyp size (inmm), learning curves, and directionality of inaccuracy (over- vs. underestimation).
RESULTS: 36 trainees from five training programs provided 1360 polyp size assessments. The feedback only (80.1%, P=0.01) and video + feedback (78.9%, P=0.02) groups had higher accuracy of polyp size classification compared with controls (71.6%). There was no significant difference in accuracy between the video only group (74.4%) and controls (P=0.42). Groups receiving feedback had higher accuracy of exact polyp size (inmm) and higher peak learning curves. Polyps were more likely to be overestimated than underestimated, and 29.3% of size inaccuracies impacted recommended surveillance intervals.
CONCLUSIONS: Our online educational module significantly improved polyp size classification. Real-time feedback appeared to be a critical component in improving accuracy. This scalable and no-cost educational module could significantly decrease under- and overutilization of colonoscopy, improving patient outcomes while increasing colonoscopy access.
Yoga-mindfulness program consisting of movements/postures (asanas), breathing practices, relaxation practices and meditation practices, together with brief talks on yoga-based coping strategies. The intervention starts with a introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks, with home assignments for about 30 minutes per day, four days per week.
FIELD: microbiology. SUBSTANCE: invention relates to the novel, safety attenuated strains Pseudomonas aeruginosa obtained by isolation of pure Pseudomonas aeruginosa according to immunotype Fischer-Delvin followed by repeated purification of isolated strain, in part, strains CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035). Also, invention relates to vaccines used for immunization against infection caused by Pseudomonas aeruginosa that involves cell envelope proteins of molecular mass from 10 000 to 100 000 Da obtained from attenuated strains, therapeutic agent for treatment of patients with infection caused by Pseudomonas aeruginosa containing immunoglobulin(s) produced by cell envelope proteins of laboratory animals and method of their preparing. Protein component of cell envelope of attenuated strain is safety and it does not show pathogenicity but has excellent ability to form antibodies and useful for preparing vaccine and therapeutic agent. EFFECT: new strains indicated above, valuable properties. 27 cl, 2 dwg, 14 tbl, 16 ex
For topical use only, not for oral, ophthalmic or intravaginal use [ see Clinical Studies ( 14) ]. 

After shaking the can well, a small amount of topical foam (e.g. a cherry-sized amount) should be expressed from the can onto the fingertips of the hand and then rubbed into acne-affected parts of the face. This should be repeated as needed until all acne-affected parts of the face are treated. If acne is present on other parts of the patient’s body (neck, shoulders, arms, back or chest), additional amounts of topical foam should also be applied to these areas. The topical foam should be applied at approximately the same time each day at least 1 hour before bedtime. The patient should not bathe, shower or swim for at least 1 hour after application of the product.
Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.